Pfizer Inc
4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from the Covid straitjacket that so many of these companies got caught up in. The pandemic obscured so much of the growth as Abbott Labs , […]
Read More
Heading to Davos, right here's what was overheard on connecting trains from Zurich to the World Economic Forum
Zurich’s principal coach station MacKenzie Sigalos DAVOS, Switzerland — It took 18 hours, a Lyft, two planes, three cross-nation practice rides, and a drive in a Volvo athletics utility car to get from midtown Manhattan to an apartment on Scalettastrasse, a snow-lined avenue in the coronary heart of Davos. The compact Swiss Alpine town is […]
Read More
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. […]
Read More
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment. […]
Read More
Cramer's 7 days in advance: Earnings year kicks off following JPMorgan Health care Convention
CNBC’s Jim Cramer on Friday instructed traders what to observe for on Wall Street next 7 days, highlighting JPMorgan‘s industry-shifting health-care meeting in San Francisco. Getting location from Monday to Thursday, the meeting is a single of the year’s most significant gatherings of key industry CEOs where they expose earnings assistance and updates on clinical […]
Read More
Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo Nordisk and Eli Lilly might use the same term for the returns they’ve realized over the past year. U.S.-listed shares of Novo Nordisk, the maker […]
Read More
Here are the big health sector themes to watch next year
An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and […]
Read More
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The weight loss drug market transformed into the pharmaceutical industry’s newest gold rush this year, as demand for costly but highly effective treatments from Novo Nordisk […]
Read More
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. […]
Read More
Is Novo Nordisk a get? Wall Avenue banking companies weigh in — and one offers it 36% draw back
For a lot of traders, the pounds loss drug boom has boosted Danish pharmaceutical big Novo Nordisk ‘s appeal this calendar year — but just one financial investment bank has reservations. “Above the coming yr, we envisage sentiment to change, most likely originally as a final result of the launch of competitor Eli Lilly ‘s […]
Read More